677 related articles for article (PubMed ID: 27775706)
1. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
[TBL] [Abstract][Full Text] [Related]
2. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.
Ganesh S; Shui X; Craig KP; Park J; Wang W; Brown BD; Abrams MT
Mol Ther; 2018 Nov; 26(11):2567-2579. PubMed ID: 30274786
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity in mice by the combination of nanoparticle-based photothermolysis and anti-PD-1 checkpoint inhibition.
Cao Q; Wang W; Zhou M; Huang Q; Wen X; Zhao J; Shi S; Geng K; Li F; Hatakeyama H; Xu C; Piwnica-Worms D; Peng W; Zhou D; Sood AK; Li C
Nanomedicine; 2020 Apr; 25():102169. PubMed ID: 32059873
[TBL] [Abstract][Full Text] [Related]
4. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.
Borchmann S; Selenz C; Lohmann M; Ludwig H; Gassa A; Brägelmann J; Lohneis P; Meder L; Mattlener J; Breid S; Nill M; Fassunke J; Wisdom AJ; Compes A; Gathof B; Alakus H; Kirsch D; Hekmat K; Büttner R; Reinhardt HC; Hallek M; Ullrich RT
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36223955
[TBL] [Abstract][Full Text] [Related]
5. Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.
Feola S; Hamdan F; Russo S; Chiaro J; Fusciello M; Feodoroff M; Antignani G; D'Alessio F; Mölsä R; Stigzelius V; Bottega P; Pesonen S; Leusen J; Grönholm M; Cerullo V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458776
[TBL] [Abstract][Full Text] [Related]
6. Rethinking immune checkpoint blockade: 'Beyond the T cell'.
Liu X; Hogg GD; DeNardo DG
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468555
[TBL] [Abstract][Full Text] [Related]
7. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract][Full Text] [Related]
8. Trends and advances in tumor immunology and lung cancer immunotherapy.
Aldarouish M; Wang C
J Exp Clin Cancer Res; 2016 Sep; 35(1):157. PubMed ID: 27686848
[TBL] [Abstract][Full Text] [Related]
9. Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine.
Liu HY; Altman A; Canonigo-Balancio AJ; Croft M
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36912535
[TBL] [Abstract][Full Text] [Related]
10. Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations.
McMahon RA; D'Souza C; Neeson PJ; Siva S
Neoplasia; 2023 Dec; 46():100940. PubMed ID: 37913654
[TBL] [Abstract][Full Text] [Related]
11. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.
Bu MT; Chandrasekhar P; Ding L; Hugo W
Pharmacol Ther; 2022 Dec; 240():108211. PubMed ID: 35577211
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.
Zelenay S; van der Veen AG; Böttcher JP; Snelgrove KJ; Rogers N; Acton SE; Chakravarty P; Girotti MR; Marais R; Quezada SA; Sahai E; Reis e Sousa C
Cell; 2015 Sep; 162(6):1257-70. PubMed ID: 26343581
[TBL] [Abstract][Full Text] [Related]
13. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Hirschhorn D; Budhu S; Kraehenbuehl L; Gigoux M; Schröder D; Chow A; Ricca JM; Gasmi B; De Henau O; Mangarin LMB; Li Y; Hamadene L; Flamar AL; Choi H; Cortez CA; Liu C; Holland A; Schad S; Schulze I; Betof Warner A; Hollmann TJ; Arora A; Panageas KS; Rizzuto GA; Duhen R; Weinberg AD; Spencer CN; Ng D; He XY; Albrengues J; Redmond D; Egeblad M; Wolchok JD; Merghoub T
Cell; 2023 Mar; 186(7):1432-1447.e17. PubMed ID: 37001503
[TBL] [Abstract][Full Text] [Related]
14. Fine tuning of the innate and adaptive immune responses by Interleukin-2.
Sakellariou C; Roser LA; Schiffmann S; Lindstedt M
J Immunotoxicol; 2024 Mar; 21(1):2332175. PubMed ID: 38526995
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blocking antibodies moonlighting as killers.
Leitner J; Battin C; Grabmeier-Pfistershammer K; Steinberger P
Eur J Immunol; 2021 Jun; 51(6):1361-1364. PubMed ID: 33954999
[TBL] [Abstract][Full Text] [Related]
16. A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response.
Kang S; Xie J; Miao J; Li R; Liao W; Luo R
Cancer Immunol Immunother; 2013 Jan; 62(1):183-90. PubMed ID: 22864395
[TBL] [Abstract][Full Text] [Related]
17. Regulation and impact of tumor-specific CD4
Guo M; Liu MYR; Brooks DG
Trends Immunol; 2024 Apr; 45(4):303-313. PubMed ID: 38508931
[TBL] [Abstract][Full Text] [Related]
18. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Swart M; Verbrugge I; Beltman JB
Front Oncol; 2016; 6():233. PubMed ID: 27847783
[TBL] [Abstract][Full Text] [Related]
19. Bioengineering strategies to enhance the interleukin-18 bioactivity in the modern toolbox of cancer immunotherapy.
Taheri M; Tehrani HA; Daliri F; Alibolandi M; Soleimani M; Shoari A; Arefian E; Ramezani M
Cytokine Growth Factor Rev; 2024 Feb; 75():65-80. PubMed ID: 37813764
[TBL] [Abstract][Full Text] [Related]
20. Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses.
Hunt KS; Alspach E
Cancer Immunol Res; 2024 Jan; 12(1):17-25. PubMed ID: 37939008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
